10-Q: Harmony Biosciences Q1 2026 Revenue Up 16.6%, R&D Surges

Harmony Biosciences reported a 16.6% increase in net product revenue for Q1 2026, driven by unit shipments and a price increase, while research and development expenses more than doubled due to significant upfront license fees.

Summary

• Harmony Biosciences reported net product revenue of $215.4 million for the three months ended March 31, 2026, a 16.6% increase compared to $184.7 million in the same period of 2025.
• Cost of product sold increased by 39.1% to $44.5 million, leading to a gross profit of $170.9 million.
• Research and development expenses significantly increased by 100.9% to $69.4 million, largely due to $32.0 million in acquired in-process R&D (IPR&D) charges.
• Sales and marketing expenses saw a modest increase of 3.2% to $31.7 million.
• General and administrative expenses rose by 4.0% to $32.5 million.
• Operating income decreased by 33.7% to $37.3 million, compared to $56.2 million in the prior year.
• Net income for the quarter was $32.5 million, a decrease from $45.6 million in Q1 2025.
• The company ended the quarter with $589.4 million in cash and cash equivalents and $229.6 million in long-term investments, totaling $870.4 million in cash and investments.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed-to-negative result; while revenue growth is positive, the significant increase in R&D expenses and the resulting drop in net income and operating income are concerning indicators for the current period.

Positives

• Net product revenue increased by 16.6% to $215.4 million, driven by a 12.1% increase in unit shipments and a 7% price increase implemented in January 2026.
• Secured formulary access for over 80% of all insured lives in the United States.
• Average number of patients on WAKIX was approximately 8,500 for the quarter.
• FDA approved WAKIX for the treatment of cataplexy in patients six years and older with narcolepsy in February 2026.
• The company has adequate supply of WAKIX to cover demand into the fourth quarter of 2028, with additional API on-hand inventory to support at least 24 months beyond this time frame.
• The company has $870.5 million in cash, cash equivalents, and investments as of March 31, 2026, providing ample liquidity for at least the next 12 months.

Negatives

• Net income decreased by 28.7% to $32.5 million from $45.6 million in the prior year's quarter.
• Operating income decreased by 33.7% to $37.3 million from $56.2 million.
• Cost of product sold increased by 39.1% to $44.5 million, and as a percentage of net product revenue, it rose from 17.3% to 20.7%.
• The effective tax rate increased from 20.3% in Q1 2025 to 18.1% in Q1 2026, though the absolute tax expense decreased due to lower pre-tax income.
• The company incurred a significant $32.0 million in acquired in-process R&D charges related to upfront license fees.

Risks

• The company is subject to patent infringement litigation related to generic versions of WAKIX, with settlement agreements allowing generic entry in mid-2030 or earlier under certain circumstances.
• Competition from other companies manufacturing and selling or developing similar products, including generic competition, poses a risk.
• The company depends on two suppliers for the active pharmaceutical ingredient (API) for WAKIX and single API suppliers for its potential product candidates.
• The company's operations are subject to clinical trial results, regulatory approvals, and the ability to obtain favorable insurance coverage and reimbursement.
• There is a risk of failure to successfully execute the growth strategy, including any delays in planned future growth.
• The company's ability to raise capital is a significant factor affecting its operations.

Future Outlook

The company expects its research and development expenses to remain significant as it advances current clinical development programs and prepares for regulatory approvals for additional indications. Sales and marketing expenses are also expected to increase to support WAKIX's indications and portfolio expansion. General and administrative expenses are anticipated to rise due to increased operational costs as a public company and potential expansion of sales and marketing teams if new products are approved. The company believes its current cash, cash equivalents, and investments are sufficient to meet operational liquidity needs for at least the next twelve months.

Management Comments

• We are cultivating a differentiated neuroscience company, rooted in innovation and driven by a commitment to addressing the unmet needs of patients living with neurological diseases.
• To date, we have focused on rare neurological diseases with a growing portfolio now spanning sleep/wake and rare epilepsy, and we are harnessing scientific insights and pioneering approaches to advance meaningful treatments that help patients thrive.

Industry Context

StockSavvy.ai notes that Harmony Biosciences' Q1 2026 results reflect a dynamic period of growth and strategic investment within the rare neurological disease sector. The significant increase in R&D spending, particularly due to IPR&D charges, indicates a strong focus on pipeline expansion and the acquisition of new therapeutic candidates, a common strategy for companies aiming to diversify and capture new market segments. The revenue growth, while positive, is tempered by rising costs, especially in cost of goods sold and R&D, which is typical for companies investing heavily in late-stage development and commercialization.

Comparison to Industry Standards

• Harmony Biosciences' revenue growth of 16.6% in Q1 2026 is robust, especially for a company focused on rare diseases, where market penetration can be challenging. This growth rate is generally considered strong compared to the broader pharmaceutical industry average, which often sees single-digit growth.
• The increase in R&D expenses to over 100% of the prior year's quarter is a significant investment. While high R&D spending is characteristic of the biotech sector, Harmony's substantial increase, driven by IPR&D, suggests aggressive pipeline development, potentially outpacing some peers who might have more organic growth in R&D.
• The rise in Cost of Goods Sold (COGS) as a percentage of revenue (from 17.3% to 20.7%) is a point of attention. While royalty payments are a standard cost in the pharmaceutical industry, an increase in this ratio can impact gross margins. Companies like Vertex Pharmaceuticals or Gilead Sciences, which have strong commercial products, often aim to maintain stable or declining COGS as a percentage of revenue through manufacturing efficiencies and scale.
• The company's net income decline, despite revenue growth, highlights the impact of increased operating expenses, particularly R&D. This is not uncommon in the biotech sector where significant upfront investments are made for future potential, but it contrasts with more mature pharmaceutical companies that may exhibit more stable profitability.

Legal Proceedings

• Harmony Biosciences and its licensor, Bioprojet, are involved in patent infringement litigation against Lupin Limited, Novugen Pharma Sdn. Bhd., Novitium Pharma LLC, Zenara Pharma Pvt. Ltd. (now Hikma), and Annora Pharma Private Limited regarding generic versions of WAKIX. Settlement agreements have been reached with Lupin, Novugen, Novitium, Zenara/Hikma, and Annora, generally allowing generic product sales starting in mid-2030 or earlier under certain circumstances.
• A lawsuit was filed on April 20, 2026, against AET Pharma US, Inc., and others, alleging infringement of U.S. Patent No. 11,623,920 in connection with AET's ANDA filing for a generic version of WAKIX.
• The company is party to a right-of-use agreement with Paragon Biosciences, LLC for office space.

Related Party Transactions

• The company has a research collaboration, option and license agreement (CiRC Agreement) with CiRC Biosciences, Inc. (CiRC), an entity controlled by Paragon Biosciences, LLC. Harmony paid an upfront fee of $15,000 to CiRC and may owe additional milestone payments and royalties.
• Harmony Biosciences has a right-of-use agreement with Paragon Biosciences, LLC for office space, incurring $73 in fees per quarter.

Stakeholder Impact

• Shareholders may be impacted by the decrease in net income and operating income, despite revenue growth, due to increased R&D and COGS.
• Patients may benefit from continued access to WAKIX and the potential for new indications and formulations, as well as new product candidates in the pipeline.
• Employees may see increased opportunities due to R&D and commercial expansion, but also face potential impacts from the company's financial performance.
• Suppliers may experience increased demand for API and manufacturing services as the company ramps up production and diversifies its supply chain.
• Creditors may be impacted by the company's debt obligations and its ability to manage its liquidity, although current cash reserves appear strong.

Next Steps

• Advance current clinical development programs and prepare for regulatory approval for additional indications.
• Continue to support WAKIX's indications and expand the product portfolio.
• Increase general and administrative expenses to support operations as a public company.
• Submit an NDA for Pitolisant GR in the second quarter of 2026.
• Initiate Phase 3 registrational trials for Pitolisant HD in narcolepsy (ONSTRIDE1) and idiopathic hypersomnia (ONSTRIDE2).
• Present topline data from the Pitolisant HD Phase 3 trials in 2027.
• Submit an Investigational Medicinal Product Dossier (IMPD) for BP-205 in the second half of 2025.
• Begin first-in-human studies for BP-205 in the fourth quarter of 2025.
• Submit a United States IND for BP-205 in mid-2026.
• Initiate a sleep-deprived healthy volunteer study for BP-205 in the second half of 2026.
• Complete Phase 3 registrational clinical trials for EPX-100 (ARGUS and LIGHTHOUSE studies) in 2027.
• Advance EPX-200 (lorcaserin liquid formulation) to the pre-IND phase.

Key Dates

Recommendation

While revenue growth is positive, the significant increase in R&D expenses, coupled with a substantial rise in cost of goods sold and a resulting decline in net income and operating income, presents a mixed picture. The company is making substantial investments in its pipeline, which could yield future growth, but the current period's profitability has been negatively impacted. The ongoing patent litigation settlements, while resolving disputes, also pave the way for generic competition in the medium term. Therefore, a 'hold' recommendation is appropriate, pending further clarity on the success and timeline of the R&D pipeline and the impact of generic entry.

Keywords

Harmony Biosciences, 10-Q, WAKIX, pitolisant, narcolepsy, neurological diseases, financial results, revenue, R&D, clinical trials, SEC filing